CLINICAL_TRIALS
trial_result
· 2019-04-17
Clinical Trial Update: Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients [Phase 2]
Summary
Phase 2 trial update on Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) has been terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Transplant Associated Microangiopathy TAM | Phase 2 | Status: TERMINATED | Results posted: 2019-04-17